UBS Group
TGTX icon

UBS Group’s TG Therapeutics TGTX Stock Holding History

UBS Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,400
Closed -$5.2M – 10922
2025
Q2 		$5.2M Buy
+144,400
New +$5.38M ﹤0.01% 3846
2015
Q1 		– Sell
-100
Closed -$2K – 9364
2014
Q4 		$2K Buy
+100
New +$1.3K ﹤0.01% 9426

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group's TGTX Position: Q1 2026 in Review

UBS Group reduced its TG Therapeutics (TGTX) stake by 5.8% in Q1 2026, selling an estimated $935K and leaving 505,650 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2794.

UBS Group first reported a position in TGTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $24.9M in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • UBS Group held 505,650 shares of TG Therapeutics worth $16.8M as of Q1 2026.
  • UBS Group sold 31,369 TG Therapeutics shares in Q1 2026, an estimated $935K.
  • TG Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2794 holding.
  • UBS Group first reported a position in TG Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's TG Therapeutics position peaked at $24.9M in Q1 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.